Cytogen has raised $10 million in a private placement with institutional investors. The Princeton, NJ-based firm said it would use the proceeds for its previously announced reacquisition of North American and Latin American rights and related expenses to its Quadramet radiopharmaceutical, from Berlex. Quadramet is a skeletal targeting agent used for the relief of bone pain in prostate cancer and other cancer patients.
By AuntMinnie.com staff writersJuly 11, 2003
Related Reading
GE, Cytogen ink fusion imaging alliance, June 24, 2003
Cytogen to reacquire Quadramet rights, June 16, 2003
Cytogen, DraxImage terminate brachytherapy agreement, April 9, 2003
Cytogen 2002 loss grows despite revenue gains, February 26, 2003
Cytogen, Draxis dispute heats up, January 28, 2003
Copyright © 2003 AuntMinnie.com
